Literature DB >> 25090263

GOLP3 is a predictor of survival in patients with hepatocellular carcinoma.

Jiang JianXin, Yu Cha, Li ZhiPeng, Xiao Jie, Zhang Hao, Chen Meiyuan, Sun ChengYi1.   

Abstract

PURPOSE: Hepatocellular carcinoma (HCC) is one of the most common solid tumors and ranks the third leading cause of cancer mortality worldwide. The purpose of this study was to examine the expression dynamics of GOLPH3 in HCC tissue samples, and explore the correlation between GOLPH3 expression and prognosis in patients with HCC.
METHODS: The levels of Golgi phosphoprotein 3 (GOLPH3) mRNA and protein in liver cancer cell lines and fresh tissues were determined by qRT-PCR and Western blotting. Additionally, the protein expression of GOLPH3 was detected by immunohistochemistry.
RESULTS: High GOLPH3 expression was positively correlated with serum AFP level (P=0.015) and tumor recurrence or metastasis (P=0.010). In addition, liver cancer patients with high GOLPH3 expression had significantly poorer overall survival (HR, 1.87; 95% CI, 1.19-2.94; P=0.006) and poorer disease-free survival (HR, 1.90; 95% CI, 1.21-2.98; P=0.005) than those with low GOLPH3 expression. The cumulative 5-year survival rate was only 35.19% (95% CI, 26.18%-44.20%) in the high GOLPH3 expression group, whereas it was 55.93% (95% CI, 43.26%-68.60%) in the low GOLPH3 expression group. Furthermore, multivariate Cox regression analysis demonstrated that the expression of GOLPH3, tumor size and tumor multiplicity were independent prognostic predictors for HCC patients.
CONCLUSION: GOLPH3 was overexpressed in HCC at both the mRNA and protein levels, and the presence of high levels of expression of GOLPH3 could serve as a novel and potential prognostic biomarker for liver cancer patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25090263

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  6 in total

Review 1.  GOLPH3 links the Golgi, DNA damage, and cancer.

Authors:  Matthew D Buschman; Juliati Rahajeng; Seth J Field
Journal:  Cancer Res       Date:  2015-01-29       Impact factor: 12.701

Review 2.  Golgi phosphoprotein3 overexpression is associated with poor survival in patients with solid tumors: a meta-analysis.

Authors:  Yaqi Jiang; Yuqi Su; Yang Zhao; Changqie Pan; Li Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 3.  The multiple cellular functions of the oncoprotein Golgi phosphoprotein 3.

Authors:  Stefano Sechi; Anna Frappaolo; Giorgio Belloni; Gianni Colotti; Maria Grazia Giansanti
Journal:  Oncotarget       Date:  2015-02-28

4.  Exploring the Molecular Mechanism and Biomakers of Liver Cancer Based on Gene Expression Microarray.

Authors:  Pengfei Liu; Wenhua Jiang; He Ren; Huilai Zhang; Jihui Hao
Journal:  Pathol Oncol Res       Date:  2015-04-25       Impact factor: 3.201

5.  Regulation of CD44 expression and focal adhesion by Golgi phosphatidylinositol 4-phosphate in breast cancer.

Authors:  Takeshi Ijuin; Yukiko Takeuchi; Yohei Shimono; Miki Fukumoto; Emi Tokuda; Tadaomi Takenawa
Journal:  Cancer Sci       Date:  2016-06-24       Impact factor: 6.716

6.  Distinct Biochemical Pools of Golgi Phosphoprotein 3 in the Human Breast Cancer Cell Lines MCF7 and MDA-MB-231.

Authors:  María J Tenorio; Breyan H Ross; Charlotte Luchsinger; Andrés Rivera-Dictter; Cecilia Arriagada; Diego Acuña; Marcelo Aguilar; Viviana Cavieres; Patricia V Burgos; Pamela Ehrenfeld; Gonzalo A Mardones
Journal:  PLoS One       Date:  2016-04-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.